Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07281495 · ClinicalTrials.gov registry record · Phase 2
Taldefgrobep Alfa in Adults With Overweight and Obesity
A Phase 2 study of Obesity and Overweight, sponsored by Biohaven Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT07281495: Active Phase 2 study of Obesity and Overweight, sponsored by Biohaven Therapeutics.
NCT07281495 is a Phase 2 study of Obesity and Overweight that is active but no longer recruiting, run by Biohaven Therapeutics. The registered enrollment target is 150 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07281495, a Phase 2 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Biohaven Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Taldefgrobep Alfa
Study Locations (20)
California
- Site-001 - Chula Vista
- Site-014 - Montclair
- Site-011 - Sacramento
- Site-018 - Tustin
Florida
- Site-020 - Orlando
- Site-008 - Palm Springs
- Site-015 - St. Petersburg
Texas
- Site-005 - Austin
- Site-012 - McKinney
- Site-013 - San Antonio
Louisiana
- Site-010 - Baton Rouge
- Site-009 - Metairie
Missouri
- Site-006 - City of Saint Peters
- Site-003 - Springfield
Illinois
- Site-007 - Chicago
Indiana
- Site-016 - Indianapolis
North Carolina
- Site-019 - Monroe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-11-24 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What the registry record for NCT07281495 still lists
NCT07281495 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07281495 names 20 study sites across 11 states, led by California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07281495 about?
NCT07281495 is a clinical study titled "Taldefgrobep Alfa in Adults With Overweight and Obesity". This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
What is the current status of trial NCT07281495?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-11-24. Estimated completion is 2026-09.
What conditions does trial NCT07281495 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07281495?
The interventions under investigation include: Placebo (DRUG), Taldefgrobep Alfa (DRUG).
Who is sponsoring clinical trial NCT07281495?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07281495 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07281495's enrollment target sits among peer trials
150 370th of 1053 higher than 668 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI